Literature DB >> 23458778

Cannabis, psychosis and the thalamus: a theoretical review.

Zoran Vukadinovic1, Merrill S Herman, Ivana Rosenzweig.   

Abstract

The role of cannabis in the etiology of schizophrenia has been documented as possibly the strongest environmental risk factor. However, the pathomechanism whereby cannabis use increases this risk has not yet been identified. We argue that this pathomechanism may involve direct effects of exogenous cannabinoids on T-type calcium channels in the thalamus. These channels are crucial for amplification of corticothalamic inputs, as well as for the ability of the thalamus to generate neuronal burst firing. Cortically induced thalamic burst firing has been found to be important in trans-thalamic cortico-cortical interactions. Therefore, any potential interference with the burst firing mode in the thalamus could lead to an impairment in these interactions, which in turn causes a relative disconnection between cortical areas. This in turn could result in reduced ability to recognize re-afferent sensory inputs and psychosis. We also argue that the effects of Δ(9)THC are more detrimental compared with the effects of cannabidiol, as the former may increase the excitability of thalamic neurons by its direct effect on T-type calcium channels.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23458778     DOI: 10.1016/j.neubiorev.2013.02.013

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  2 in total

1.  Subcortical Local Functional Hyperconnectivity in Cannabis Dependence.

Authors:  Peter Manza; Dardo Tomasi; Nora D Volkow
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-11-22

2.  A regulatory variant of CHRM3 is associated with cannabis-induced hallucinations in European Americans.

Authors:  Zhongshan Cheng; Chureerat Phokaew; Yi-Ling Chou; Dongbing Lai; Jacquelyn L Meyers; Arpana Agrawal; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter
Journal:  Transl Psychiatry       Date:  2019-11-18       Impact factor: 6.222

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.